Back to Search
Start Over
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
- Source :
- Cancer Treatment Reviews. 60:109-119
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.
- Subjects :
- Proto-Oncogene Proteins B-raf
0301 basic medicine
Oncology
medicine.medical_specialty
Colorectal cancer
medicine.medical_treatment
Population
Antineoplastic Agents
Targeted therapy
Unmet needs
03 medical and health sciences
0302 clinical medicine
Internal medicine
Epidemiology
Biomarkers, Tumor
medicine
Humans
Radiology, Nuclear Medicine and imaging
Molecular Targeted Therapy
Neoplasm Metastasis
Treatment resistance
education
neoplasms
education.field_of_study
business.industry
Molecular pathogenesis
Raf kinase
General Medicine
medicine.disease
digestive system diseases
030104 developmental biology
030220 oncology & carcinogenesis
Colorectal Neoplasms
business
Subjects
Details
- ISSN :
- 03057372
- Volume :
- 60
- Database :
- OpenAIRE
- Journal :
- Cancer Treatment Reviews
- Accession number :
- edsair.doi.dedup.....e34ea12fa26c247215f201cf2d48dccd